---
title: "Deramiocel (CAP-1002) in Duchenne muscular dystrophy: References"
description: "Reference list for the formulary evidence report on Deramiocel (CAP-1002) in Duchenne muscular dystrophy. 89 cited documents."
canonical: "https://www.evicenter.com/drugs/deramiocel--duchenne-muscular-dystrophy/references"
published: "2026-09-14T15:39:06-04:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Deramiocel (CAP-1002) in Duchenne muscular dystrophy: References

<a id="references"></a>

## 5 References

1. [Aminzadeh et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/29478899/)
2. [Aminzadeh et al. (2026)](https://doi.org/10.1016/j.stemcr.2026.102889)
3. [Andrews et al. (2018)](https://publications.aap.org/pediatrics/article/142/1/e20174006/37450/Implementation-of-Duchenne-Muscular-Dystrophy-Care)
4. [Audhya et al. (2023)](https://link.springer.com/article/10.1186/s41687-023-00671-y)
5. [Avila-Smirnow et al. (2025)](https://www.nature.com/articles/s41598-025-27480-1)
6. [Bever et al. (2026)](https://link.springer.com/10.1007/s12325-026-03700-6)
7. [Bourke et al. (2022)](https://openheart.bmj.com/content/9/2/e001977)
8. [Broomfield et al. (2024)](https://doi.org/10.1007/s41669-023-00450-x)
9. [Capricor Therapeutics (2017)](https://www.capricor.com/investors/news-events/press-releases/detail/135/capricor-receives-rare-pediatric-disease-designation-from)
10. [Capricor Therapeutics (2018)](https://www.capricor.com/investors/news-events/press-releases/detail/119/capricor-receives-fda-regenerative-medicine-advanced)
11. [Capricor Therapeutics AAN presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_98d9213fd51a80017b9973bdbafc2d14/capricor/files/631961/CAPR_AAN_%282026_Presentation%29.pdf)
12. [Capricor Therapeutics advisory committee update announcement (2026)](https://www.capricor.com/investors/news-events/press-releases/detail/351/capricor-therapeutics-provides-update-on-fda-advisory)
13. [Capricor Therapeutics BLA submission announcement (2025)](https://www.capricor.com/investors/news-events/press-releases/detail/303/capricor-therapeutics-completes-submission-of-biologics)
14. [Capricor Therapeutics complaint (2026)](https://www.capricor.com/investors/sec-filings/all-sec-filings/content/0001104659-26-057221/capr-20260507xex99d2.htm)
15. [Capricor Therapeutics FDA Advisory Committee briefing document (2026)](https://www.fda.gov/media/193840/download)
16. [Capricor Therapeutics first quarter 2026 results announcement (2026)](https://www.sec.gov/Archives/edgar/data/1133869/000110465926059380/capr-20260512xex99d1.htm)
17. [Capricor Therapeutics Form 10-K (2020)](https://www.sec.gov/Archives/edgar/data/1133869/000110465920039272/tm205377d1_10k.htm)
18. [Capricor Therapeutics Form 10-K (2026)](https://www.capricor.com/investors/sec-filings/all-sec-filings/content/0001104659-26-029580/capr-20251231x10k.htm)
19. [Capricor Therapeutics Form 10-Q (2026)](https://www.capricor.com/investors/sec-filings/all-sec-filings/content/0001104659-26-060382/capr-20260331x10q.htm)
20. [Capricor Therapeutics Form 8-K (2026)](https://www.capricor.com/investors/sec-filings/all-sec-filings/content/0001104659-26-057221/capr-20260507x8k.htm)
21. [Capricor Therapeutics fourth quarter 2018 results announcement (2019)](https://www.capricor.com/investors/news-events/press-releases/detail/88/capricor-therapeutics-reports-fourth-quarter-and-full-year)
22. [Capricor Therapeutics HOPE publication announcement (2019)](https://www.capricor.com/investors/news-events/press-releases/detail/91/neurology-publishes-study-reporting-significant)
23. [Capricor Therapeutics HOPE-2 protocol (2019)](https://cdn.clinicaltrials.gov/large-docs/80/NCT03406780/Prot_001.pdf)
24. [Capricor Therapeutics HOPE-2 statistical analysis plan (2020)](https://cdn.clinicaltrials.gov/large-docs/80/NCT03406780/SAP_002.pdf)
25. [Capricor Therapeutics HOPE-2-OLE statistical analysis plan (2024)](https://cdn.clinicaltrials.gov/large-docs/76/NCT04428476/SAP_001.pdf)
26. [Capricor Therapeutics HOPE-3 MDA 2026 data announcement (2026)](https://www.capricor.com/investors/news-events/press-releases/detail/339/capricor-therapeutics-announces-late-breaking-hope-3-data)
27. [Capricor Therapeutics HOPE-3 topline results announcement (2025)](https://www.capricor.com/investors/news-events/press-releases/detail/331/capricor-therapeutics-announces-positive-topline-results)
28. [Capricor Therapeutics HOPE-OLE protocol (2018)](https://cdn.clinicaltrials.gov/large-docs/64/NCT06304064/Prot_000.pdf)
29. [Capricor Therapeutics HOPE-OLE statistical analysis plan (2019)](https://cdn.clinicaltrials.gov/large-docs/64/NCT06304064/SAP_001.pdf)
30. [Capricor Therapeutics January 2026 regulatory update announcement (2026)](https://www.capricor.com/investors/news-events/press-releases/detail/335/capricor-therapeutics-provides-regulatory-update-on)
31. [Capricor Therapeutics July 2025 regulatory update announcement (2025)](https://www.capricor.com/investors/news-events/press-releases/detail/319/capricor-therapeutics-provides-regulatory-update-on)
32. [Capricor Therapeutics legal action announcement (2026)](https://www.capricor.com/investors/news-events/press-releases/detail/343/capricor-therapeutics-takes-legal-action-to-protect-patient)
33. [Capricor Therapeutics MDA 2026 presentation announcement (2026)](https://www.capricor.com/investors/news-events/press-releases/detail/336/capricor-therapeutics-announces-late-breaking-presentation)
34. [Capricor Therapeutics MDA presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_72a8420b8089fb55954d5909808b3da2/capricor/files/631961/MDA_2026_CAPR_3.11.26_late-breaker.pdf)
35. [Capricor Therapeutics new PDUFA date announcement (2026)](https://www.capricor.com/investors/news-events/press-releases/detail/338/capricor-therapeutics-announces-establishment-of-new-pdufa)
36. [Capricor Therapeutics PDUFA date extension announcement (2026)](https://www.capricor.com/investors/news-events/press-releases/detail/354/capricor-therapeutics-announces-extension-of-pdufa-target)
37. [Capricor Therapeutics PPMD 2026 presentation announcement (2026)](https://www.capricor.com/investors/news-events/press-releases/detail/347/capricor-to-present-positive-five-year-hope-2-ole-data-and)
38. [Capricor Therapeutics PPMD presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_44a0a21427a90b1030ae38c70ae1faf7/capricor/files/PPMD_2026_HOPE-2_OLE_Late-breaker_6.27.26.pdf)
39. [Capricor Therapeutics second quarter 2026 results announcement (2026)](https://www.capricor.com/investors/news-events/press-releases/detail/353/capricor-therapeutics-reports-second-quarter-2026-financial)
40. [Capricor Therapeutics third quarter 2026 results announcement (2026)](https://www.capricor.com/investors/news-events/press-releases/detail/359/capricor-therapeutics-reports-third-quarter-2026-financial)
41. [CDC (2009)](https://www.cdc.gov/mmwr/preview/mmwrhtml/mm5840a1.htm)
42. [Crisafulli et al. (2020)](https://link.springer.com/article/10.1186/s13023-020-01430-8)
43. [DMD Care Considerations Working Group care considerations part 1 (2018)](https://www.parentprojectmd.org/wp-content/uploads/2018/06/Duchenne_CareConsiderations_2018_Part1.pdf)
44. [DMD Care Considerations Working Group care considerations part 2 (2018)](https://www.parentprojectmd.org/wp-content/uploads/2018/06/Duchenne_CareConsiderations_2018_Part2.pdf)
45. [DMD Care Considerations Working Group care considerations part 3 (2018)](https://www.parentprojectmd.org/wp-content/uploads/2018/06/Duchenne_CareConsiderations_2018_Part3.pdf)
46. [FDA (2024)](https://www.fda.gov/news-events/press-announcements/fda-approves-nonsteroidal-treatment-duchenne-muscular-dystrophy)
47. [FDA (2025)](https://www.fda.gov/news-events/press-announcements/fda-approves-new-safety-warning-and-revised-indication-limits-use-elevidys-following-reports-fatal)
48. [FDA briefing document (2026)](https://www.fda.gov/media/193839/download)
49. [FDA presentation (2026)](https://www.fda.gov/media/193912/download)
50. [Gandolla et al. (2020)](https://journals.plos.org/plosone/article?id=10.1371%2Fjournal.pone.0239064)
51. [Gillman et al. (2025)](https://www.frontiersin.org/journals/neurology/articles/10.3389/fneur.2025.1509174/full)
52. [Iannaccone et al. (2026)](https://www.neurology.org/doi/10.1212/WNL.0000000000217921)
53. [Innis et al. (2025)](https://link.springer.com/article/10.1186/s13023-025-03794-1)
54. [Kariyawasam et al. (2022)](https://www.nature.com/articles/s41431-022-01138-2)
55. [Klimchak et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10391028/)
56. [Landfeldt et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4141999/)
57. [Landfeldt et al. (2016)](https://link.springer.com/article/10.1007/s00415-016-8080-9)
58. [Landfeldt et al. (2017)](https://link.springer.com/article/10.1007/s40273-016-0461-5)
59. [Landfeldt et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/29904912/)
60. [Landfeldt et al. (2020)](https://link.springer.com/article/10.1007/s10654-020-00613-8)
61. [Landfeldt et al. (2026)](https://link.springer.com/article/10.1007/s40273-026-01610-7)
62. [Lempriere (2022)](https://pubmed.ncbi.nlm.nih.gov/35396359/)
63. [Li et al. (2025)](https://d1io3yog0oux5.cloudfront.net/_720140307f1b6c7261a7b3c4d8426889/capricor/files/pages/capricor/db/2348/authors/biomedicines-13-02652_%28Capricor%29.pdf)
64. [Mayhew et al. (2013)](https://onlinelibrary.wiley.com/doi/10.1111/dmcn.12213)
65. [Mayhew et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/31538331/)
66. [McDonald et al. (2022)](https://d1io3yog0oux5.cloudfront.net/capricor/files/pages/our-science/publications/Lancet-Paper-CAP1002.pdf)
67. [McDonald et al. (2023)](https://d1io3yog0oux5.cloudfront.net/_e7a3fba205f4fce31284150e8f43c824/capricor/files/Long_Term_Safety_and_Efficacy_of_CAP-1002_in_late-stage_patients_with_DMD_Poster.pdf)
68. [McDonald et al. (2024)](https://d1io3yog0oux5.cloudfront.net/_958553a36c8534969b6e9dd543064101/capricor/files/pages/our-science/publications/WMS_2024_Poster_%28Capricor%29.pdf)
69. [McDonald et al. (2025)](https://d1io3yog0oux5.cloudfront.net/_e9bad581d8d3c98ff5505cb2a64c3ec9/capricor/files/pages/our-science/publications/MDA_2025_poster_Final.pdf)
70. [McDonald et al. (2026)](https://d1io3yog0oux5.cloudfront.net/_fe6d5f8f9bad70880b7ed653911dd676/capricor/files/Lancet_%28HOPE-3%29_Phase_3_publication.pdf)
71. [MedlinePlus Genetics](https://medlineplus.gov/genetics/condition/duchenne-and-becker-muscular-dystrophy/)
72. [Muscular Dystrophy Association](https://www.mda.org/disease/duchenne-muscular-dystrophy/medical-management)
73. [Pane et al. (2014)](https://pubmed.ncbi.nlm.nih.gov/24440357/)
74. [Pane et al. (2018)](https://journals.plos.org/plosone/article?id=10.1371%2Fjournal.pone.0199223)
75. [PharmacoEconomics–Open (2026)](https://link.springer.com/article/10.1007/s41669-026-00646-x)
76. [Quinlivan et al. (2021)](https://journals.sagepub.com/doi/10.3233/JND-200609)
77. [Rogers et al. (2019)](https://insight.jci.org/articles/view/125754)
78. [Rogers et al. (2025)](https://www.cirm.ca.gov/about-cirm/publications/long-term-preservation-muscle-function-and-structure-repeated-administration-cardiosphere-derived-cells-mdx-mice/)
79. [Scavina et al. (2026)](https://link.springer.com/article/10.1007/s41669-025-00612-z)
80. [Smith et al. (2025)](https://www.ispor.org/heor-resources/presentations-database/presentation-cti/ispor-2025/poster-session-5/impact-of-newborn-screening-for-duchenne-muscular-dystrophy-a-model-based-analysis)
81. [Soslow (2026)](https://d1io3yog0oux5.cloudfront.net/_7633595f5f8ea5d280c4a86092c10a63/capricor/files/CAPR_%28ASGCT_2026%29_Soslow.pdf)
82. [Soslow et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37288563/)
83. [Strober et al. (2026)](https://link.springer.com/article/10.1186/s12883-025-04531-8)
84. [Szabo et al. (2020)](https://link.springer.com/article/10.1007/s11136-019-02355-x)
85. [Tang and Yokota (2024)](https://pubmed.ncbi.nlm.nih.gov/38291016/)
86. [Taylor et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6396968/)
87. [University of California, Davis (2025)](https://clinicaltrials.ucdavis.edu/trial/NCT04428476)
88. [University of California, Davis (2026)](https://clinicaltrials.ucdavis.edu/trial/NCT05126758)
89. [Yip et al. (2026)](https://jheor.org/article/158537-systematic-literature-reviews-of-health-state-utility-values-costs-and-healthcare-resource-use-in-duchenne-muscular-dystrophy)

## Related pages
- [Deramiocel (CAP-1002): Duchenne muscular dystrophy](https://www.evicenter.com/drugs/deramiocel--duchenne-muscular-dystrophy) · [Markdown](https://www.evicenter.com/drugs/deramiocel--duchenne-muscular-dystrophy.md)
- [Deramiocel (CAP-1002) in Duchenne muscular dystrophy: Terms and abbreviations](https://www.evicenter.com/drugs/deramiocel--duchenne-muscular-dystrophy/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/deramiocel--duchenne-muscular-dystrophy/terms-and-abbreviations.md)
- [Deramiocel (CAP-1002): Duchenne muscular dystrophy](https://www.evicenter.com/drugs/deramiocel--duchenne-muscular-dystrophy/executive-summary) · [Markdown](https://www.evicenter.com/drugs/deramiocel--duchenne-muscular-dystrophy/executive-summary.md)
- [Deramiocel (CAP-1002) in Duchenne muscular dystrophy: Product information and disease description](https://www.evicenter.com/drugs/deramiocel--duchenne-muscular-dystrophy/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/deramiocel--duchenne-muscular-dystrophy/product-information-and-disease-description.md)
- [Deramiocel (CAP-1002) in Duchenne muscular dystrophy: Clinical evidence](https://www.evicenter.com/drugs/deramiocel--duchenne-muscular-dystrophy/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/deramiocel--duchenne-muscular-dystrophy/clinical-evidence.md)
- [Deramiocel (CAP-1002) in Duchenne muscular dystrophy: Economic information and modeling report](https://www.evicenter.com/drugs/deramiocel--duchenne-muscular-dystrophy/economics) · [Markdown](https://www.evicenter.com/drugs/deramiocel--duchenne-muscular-dystrophy/economics.md)
- [Deramiocel (CAP-1002) in Duchenne muscular dystrophy: prevalence by geography](https://www.evicenter.com/drugs/deramiocel--duchenne-muscular-dystrophy/prevalence) · [Markdown](https://www.evicenter.com/drugs/deramiocel--duchenne-muscular-dystrophy/prevalence.md)
- [Deramiocel (CAP-1002) in Duchenne muscular dystrophy: cost-effectiveness analyses and utility weights](https://www.evicenter.com/drugs/deramiocel--duchenne-muscular-dystrophy/cost-effectiveness-analyses) · [Markdown](https://www.evicenter.com/drugs/deramiocel--duchenne-muscular-dystrophy/cost-effectiveness-analyses.md)
